However, some patients still require close monitoring based on their condition and response
Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen Summary of Product Characteristics
Funding The present study was supported by the National Natural Science Foundation of China (82422003), Huazhong University of Science and Technology Fundamental Research Program, the Tongji Hospital (HUST) Foundation for Excellent Young Scientists and, Hubei Provincial Medical Youth Elite Talent Program (SCZ202412), the Tongji Hospital (HUST) Cultivation Program (2024B35)
Benefits may include: no injections required easier daily use greater accessibility for patients improved long-term treatment compliance If successful, oral medications could make advanced metabolic therapies more accessible worldwide
SURPASS 2 trial Tirzepatide versus Semaglutide for weight loss in diabetic patients (weight loss in kg and by percentage of body weight), lipid levels Tirzepatide is licensed for weight loss and treatment of obesity under the brand name Zepbound, while Semaglutide is licensed under the brand name Semaglutide
doi: 10.1136/bmj.m997
